AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).

Trial Details

NCT ID
NCT07285694
Phase
PHASE1 / PHASE2
Sponsor
Arsenal Biosciences, Inc.
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • AB-3028
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Fairway, Kansas, United States|39.02223,-94.6319

Key Eligibility Criteria

  • At least 18 years of age at time of signing informed consent form.
  • Histologically confirmed adenocarcinoma of the prostate, meeting all of the following criteria:
  • Documented progressive metastatic castration-resistant prostate cancer (mCRPC) based on PCWG3 criteria.
  • Prior prostate cancer treatment with at least 1 novel androgen receptor pathway inhibitor (ARPI) therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →